Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis

NCT00539695 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00539695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00539695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis
Lead sponsor
Baylor College of Medicine
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
March 31, 2014
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myelogenous leukemia, all, aml, chronic myelogenous leukemia, hodgkin lymphoma, myelodysplastic syndrome, myeloproliferative disorder, non-hodgkin lymphoma, non-malignant diseases requiring allogeneic hsct